MeVis Medical Solutions Valuation

Q: What is the Fair Price of M3V when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

M3V (€24) is trading below our estimate of [[fair value]] (€89.23)

Is M3V undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of M3V when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: M3V (€24) is trading below our estimate of fair value (€89.23)

Significantly Below Fair Value: M3V is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for M3V?

Key metric: As M3V is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for M3V. This is calculated by dividing M3V's market cap by their current earnings.
What is M3V's PE Ratio?
PE Ratio	7.8x
Earnings	€5.75m
Market Cap	€45.14m

M3V key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.3x
Enterprise Value/EBITDA	8.3x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does M3V's PE Ratio compare to its peers?

The above table shows the PE ratio for M3V vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	24.3x
AJ91 DocCheck	17.2x	n/a	€42.1m
COP CompuGroup Medical SE KGaA	28.9x	32.9%	€726.9m
NXU Nexus	44.2x	17.1%	€1.2b
HAEK HAEMATO	7.1x	n/a	€68.0m
M3V MeVis Medical Solutions	7.8x	n/a	€45.1m

Price-To-Earnings vs Peers: M3V is good value based on its Price-To-Earnings Ratio (7.8x) compared to the peer average (24.3x).

Price to Earnings Ratio vs Industry

How does M3V's PE Ratio compare vs other companies in the European Healthcare Services Industry?

2 Companies	Price / Earnings	Estimated Growth	Market Cap

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: M3V is good value based on its Price-To-Earnings Ratio (7.8x) compared to the European Healthcare Services industry average (18.6x).

Price to Earnings Ratio vs Fair Ratio

What is M3V's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

M3V PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	7.8x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate M3V's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Shandong Weigao Group Medical Polymer

HK$20.1b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.52

-1.0%

-38.8%

LNA Santé

€244.4m

Engages in the management and operation of health establishments.

2N3

€23.25

-6.1%

16.0%

OrbusNeich Medical Group Holdings

HK$3.4b

An investment holding company, researches, develops, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People’s Republic of China, and the United States.

Q8T

HK$0.51

12.2%

-43.3%